https://scholars.lib.ntu.edu.tw/handle/123456789/517570
標題: | Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness | 作者: | Tsai Y.-C. TSEN-FANG TSAI |
公開日期: | 2017 | 出版社: | SAGE Publications Ltd | 卷: | 9 | 期: | 11 | 起(迄)頁: | 277-294 | 來源出版物: | Therapeutic Advances in Musculoskeletal Disease | 摘要: | Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38). ? 2017, ? The Author(s), 2017. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033234127&doi=10.1177%2f1759720X17735756&partnerID=40&md5=17c5d91e5e8ec68f3f5568b310c15461 https://scholars.lib.ntu.edu.tw/handle/123456789/517570 |
ISSN: | 1759-720X | DOI: | 10.1177/1759720X17735756 | SDG/關鍵字: | anakinra; briakinumab; brodalumab; canakinumab; cytokine; daclizumab; etanercept; guselkumab; interleukin 13; interleukin 15; interleukin 16; interleukin 18; interleukin 19; interleukin 21; interleukin 24; interleukin 27; interleukin 33; interleukin 35; interleukin 37; interleukin 38; interleukin 9; ixekizumab; placebo; rilonacept; risankizumab; secukinumab; tildrakizumab; tocilizumab; tumor necrosis factor; unclassified drug; ustekinumab; art; arthralgia; cardiovascular disease; drug efficacy; drug safety; fatigue; headache; human; meta analysis (topic); neutropenia; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; psoriasis; Psoriasis Area and Severity Index; randomized controlled trial (topic); Review; rhinopharyngitis; treatment response; upper respiratory tract infection |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。